EcoDrugPlus

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSCHAG00000024300
Gene Symbol: PSMB9A
1 Cross references
209 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSCHAG00000024898
Gene Symbol: PSMB9A
1 Cross references
209 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSCHAG00000007125
Gene Symbol: PSMD2
1 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSCHAG00000012208
Gene Symbol: PSMD4A
1 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSCHAG00000003778
Gene Symbol: PSMC1
3 Cross references
293 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSCHAG00000025010
Gene Symbol: PSMC2
3 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSCHAG00000000310
Gene Symbol: PSMC3
3 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSCHAG00000016362
Gene Symbol: PSMC4
1 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSCHAG00000009180
Gene Symbol: PSMC5
1 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSCHAG00000006777
Gene Symbol: PSMC6
3 Cross references
236 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSCHAG00000020333
Gene Symbol: PSMD1
1 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSCHAG00000002861
Gene Symbol: PSMD12
1 Cross references
222 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).